609
Views
49
CrossRef citations to date
0
Altmetric
Articles

Administration-Time-Dependent Effects of Hypertension Treatment on Ambulatory Blood Pressure in Patients With Chronic Kidney Disease

, , , , , , , , , & show all
Pages 159-175 | Received 01 Mar 2012, Accepted 13 Apr 2012, Published online: 25 Oct 2012

REFERENCES

  • Agarwal R, Andersen MJ. (2005). Correlates of systolic hypertension in patients with chronic kidney disease. Hypertension 46:514–520.
  • Agarwal R, Andersen MJ. (2006a). Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease. Kidney Int. 69:1175–1180.
  • Agarwal R, Andersen MJ. (2006b). Blood pressure recordings within and outside the clinic and cardiovascular events in chronic kidney disease. Am. J. Nephrol. 26:503–510.
  • Agarwal R, Peixoto AJ, Santos SFF, Zoccali C. (2009). Out-of-office blood pressure monitoring in chronic kidney disease. Blood Press. Monit. 14:2–11.
  • Amar J, Vernier I, Rossignol E, Bongard V, Arnaud C, Conte JJ, Salvador M, Chamontin B. (2000). Nocturnal blood pressure and 24-hour pulse pressure are potent indicators of mortality in hemodialysis patients. Kidney Int. 57:2485–2491.
  • American Diabetes Association. (2007). Diagnosis and classification of diabetes mellitus. Diabetes Care 30(Suppl 1):S42–S47.
  • Asmar R, Vol S, Brisac AM, Tichet J, Topouchian J. (2001). Reference values for clinic pulse pressure in a nonselected population. Am. J. Hypertens. 14:415–418.
  • Ayala DE, Hermida RC, Mojón A, Fernández JR. (2013a). Cardiovascular risk of resistant hypertension: dependence on treatment-time regimen of blood pressure-lowering medications. Chronobiol. Int. 30: 340–352.
  • Ayala DE, Moyá A, Crespo JJ, Castiñeira C, Domínguez-Sardiña M, Gomara S, Sineiro E, Mojón A, Fontao MJ, Hermida RC, on behalf of the Hygia Project Investigators. (2013b). Circadian pattern of ambulatory blood pressure in hypertensive patients with and without type 2 diabetes. Chronobiol Int. 30: 99–115.
  • Ben-Dov IZ, Kark JD, Ben-Ishay D, Mekler J, Ben-Arie L, Bursztyn M. (2007). Predictors of all-cause mortality in clinical ambulatory monitoring. Unique aspects of blood pressure during sleep. Hypertension 49:1235–1241.
  • Benetos A, Safar M, Rudnichi A, Smulyan H, Richard JI, Ducimetiere P, Guize L. (1997). Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 30:1410–1415.
  • Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Björklund-Bodegård K, Richart T, Ohkubo T, Kuznetsova T, Torp-Pedersen CH, Lind L, Ibsen H, Imai Y, Wang J, Sandoya E, O'Brien E, Staessen JA. (2007). Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet 370:1219–1229.
  • Bouhanick B, Bongard V, Amar J, Bousquel S, Chamontin B. (2008). Prognostic value of nocturnal blood pressure and reverse-dipping status on the occurrence of cardiovascular events in hypertensive diabetic patients. Diabetes Metab. 34:560–567.
  • Brotman DJ, Davidson MB, Boumitri M, Vidt DG. (2008). Impaired diurnal blood pressure variation and all-cause mortality. Am. J. Hypertens. 21:92–97.
  • Davidson MB, Hix JK, Vidt DG, Brotman DJ. (2006). Association of impaired diurnal blood pressure variation with a subsequent decline in glomerular filtration rate. Arch. Intern. Med. 166:846–852.
  • de la Sierra A, Redon J, Banegas JR, Segura J, Parati G, Gorostidi M, de la Cruz JJ, Sobrino J, Llisterri JL, Alonso J, Vinyoles E, Pallarés V, Sarría A, Aranda P, Ruilope LM, for the Spanish Society of Hypertension Ambulatory Blood Pressure Monitoring Registry Investigators. (2009). Prevalence and factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension 53:466–472.
  • Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hond E, McCormack P, Staessen JA, O'Brien E. (2005). Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 46:156–161.
  • Dolan E, Thijs L, Li Y, Atkins N, McCormack P, McClory S, O'Brien E, Staessen JA, Stanton AV. (2006). Ambulatory arterial stiffness index as a predictor of cardiovascular mortality in the Dublin Outcome Study. Hypertension 47:365–370.
  • Eguchi K, Pickering TG, Hoshide S, Ishikawa J, Ishikawa S, Schwartz J, Shimada K, Kario K. (2008). Ambulatory blood pressure is a better marker than clinic blood pressure in predicting cardiovascular events in patients with/without type 2 diabetes. Am. J. Hypertens. 21:443–450.
  • Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML, De Bacquer DA. (2008). Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 51:55–61.
  • Fan HQ, Li Y, Thijs L, Hansen TW, Boggia J, Kikuya M, Björklund-Bodegard K, Richart T, Ohkubo T, Jeppesen J, Torp-Pedersen C, Dolan E, Kuznetsova T, Stolarz-Skrzypek K, Tikhonoff V, Malyutina S, Casiglia E, Nikitin Y, Lind L, Sandoya E, Kawecka-Jaszcz K, Imai Y, Ibsen H, O'Brien E, Wang J, Staessen JA. (2010). Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J. Hypertens. 28:2036–2045.
  • Fernández JR, Hermida RC. (1998). Inferential statistical method for analysis of nonsinusoidal hybrid time series with unequidistant observations. Chronobiol. Int. 15:191–204.
  • Fernández JR, Mojón A, Hermida RC. (2004). Comparison of parameters from rhythmometric models with multiple components on hybrid data. Chronobiol. Int. 21:467–482.
  • Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. (1999). Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 100:354–360.
  • Gallerani M, Portaluppi F, Grandi E, Manfredini R. (1997). Circadian rhythmicity in the occurrence of spontaneous acute dissection and rupture of thoracic aorta. J. Thorac. Cardiovasc. Surg. 113:603–604.
  • Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Frauss RM, Savage PJ, Smith SC, Spertus JA, Costa F. (2005). Diagnosis and management of the metabolic syndrome. An American Hearty Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752.
  • Hermida RC. (1999). Time-qualified reference values for 24 h ambulatory blood pressure monitoring. Blood Press. Monit. 4:137–147.
  • Hermida RC. (2007). Ambulatory blood pressure monitoring in the prediction of cardiovascular events and effects of chronotherapy: rationale and design of the MAPEC study. Chronobiol. Int. 24:749–775.
  • Hermida RC, Ayala DE. (2003). Sampling requirements for ambulatory blood pressure monitoring in the diagnosis of hypertension in pregnancy. Hypertension 42:619–624.
  • Hermida RC, Ayala DE. (2009). Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing. Hypertension 54:40–46.
  • Hermida RC, Fernández JR. (1996). Computation of time-specified tolerance intervals for ambulatorily monitored blood pressure. Biomed. Instrum. Technol. 30:257–266.
  • Hermida RC, Smolensky MH. (2004). Chronotherapy of hypertension. Curr. Opin. Nephrol. Hypertens. 13:501–505.
  • Hermida RC, Mojón A, Fernández JR, Ayala DE. (1996). Computer-based medical system for the computation of blood pressure excess in the diagnosis of hypertension. Biomed. Instrum. Technol. 30:267–283.
  • Hermida RC, Fernández JR, Mojón A, Ayala DE. (2000). Reproducibility of the hyperbaric index as a measure of blood pressure excess. Hypertension 35:118–125.
  • Hermida RC, Ayala DE, Fernández JR, Mojón A, Alonso I, Calvo C. (2002a). Modeling the circadian variability of ambulatorily monitored blood pressure by multiple-component analysis. Chronobiol. Int. 19:461–481.
  • Hermida RC, Calvo C, Ayala DE, Fernández JR, Ruilope LM, López JE. (2002b). Evaluation of the extent and duration of the “ABPM effect” in hypertensive patients. J. Am. Coll. Cardiol. 40:710–717.
  • Hermida RC, Calvo C, Ayala DE, Mojón A, López JE. (2002c). Relationship between physical activity and blood pressure in dipper and nondipper hypertensive patients. J. Hypertens. 20:1097–1104.
  • Hermida RC, Mojón A, Fernández JR, Alonso I, Ayala DE. (2002d). The tolerance-hyperbaric test: a chronobiologic approach for improved diagnosis of hypertension. Chronobiol. Int. 19:1183–1211.
  • Hermida RC, Calvo C, Ayala DE, Domínguez MJ, Covelo M, Fernández JR, Mojón A, López JE. (2003a). Administration-time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension 42:283–290.
  • Hermida RC, Calvo C, Ayala DE, López JE, Fernández JR, Mojón A, Domínguez MJ, Covelo M. (2003b). Seasonal variation of fibrinogen in dipper and nondipper hypertensive patients. Circulation 108:1101–1106.
  • Hermida RC, Ayala DE, Calvo C. (2005). Administration time-dependent effects of antihypertensive treatment on the circadian pattern of blood pressure. Curr. Opin. Nephrol. Hypertens. 14:453–459.
  • Hermida RC, Ayala DE, Calvo C, Portaluppi F, Smolensky MH. (2007a). Chronotherapy of hypertension: administration-time dependent effects of treatment on the circadian pattern of blood pressure. Adv. Drug Deliv. Rev. 59:923–939.
  • Hermida RC, Ayala DE, Fernández JR, Calvo C. (2007b). Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension. Hypertension 50:715–722.
  • Hermida RC, Ayala DE. Fernandez JR, Mojón A, Calvo C. (2007c). Influence of measurement duration and frequency on ambulatory blood pressure monitoring. Rev. Esp. Cardiol. 60:131–138.
  • Hermida RC, Ayala DE, Chayán L, Mojón A, Fernández JR. (2009). Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients. Chronobiol. Int. 26:61–79.
  • Hermida RC, Ayala DE, Fontao MJ, Mojón A, Alonso I, Fernández JR. (2010a). Administration-time-dependent effects of spirapril on ambulatory blood pressure in uncomplicated essential hypertension. Chronobiol. Int. 27:560–574.
  • Hermida RC, Ayala DE, Fontao MJ, Mojón A, Fernández JR. (2010b). Chronotherapy with valsartan/amlodipine combination in essential hypertension: improved blood pressure control with bedtime dosing. Chronobiol. Int. 27:1287–1303.
  • Hermida RC, Ayala DE, Mojón A, Fernández JR. (2010c). Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol. Int. 27:1629–1651.
  • Hermida RC, Ayala DE, Fernández JR, Portaluppi F, Fabbian F, Smolensky MH. (2011a). Circadian rhythms in blood pressure regulation and optimization of hypertension treatment with ACE inhibitor and ARB medications. Am. J. Hypertens. 24:383–391.
  • Hermida RC, Ayala DE, Mojón A, Fernández JR. (2011b). Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J. Am. Coll. Cardiol. 58:1165–1173.
  • Hermida RC, Ayala DE, Mojón A, Fernández JR. (2011c). Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care 34:1270–1276.
  • Hermida RC, Ayala DE, Mojón A, Fernández JR. (2011d). Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J. Am. Soc. Nephrol. 22:2313–2321.
  • Hermida RC, Ayala DE, Mojón A, Fontao MJ, Fernández JR. (2011e). Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing. Chronobiol. Int. 28:601–610.
  • Hermida RC, Ayala DE, Mojón A, Fernández JR. (2012a). Sleep-time blood pressure as a therapeutic target for cardiovascular risk reduction in type 2 diabetes. Am. J. Hypertens. 25:325–334.
  • Hermida RC, Ayala DE, Mojón A, Fernández JR. (2012b). Sleep-time blood pressure and the prognostic value of isolated-office and masked hypertension. Am. J. Hypertens. 25:297–305.
  • Hermida RC, Ayala DE, Fernández JR, Mojón A. (2013a). Sleep-time blood pressure: prognostic value and relevance as a therapeutic target for cardiovascular risk reduction. Chronobiol. Int. 30: 68–86.
  • Hermida RC, Ayala DE, Fernández JR, Mojón A, Smolensky MH, Fabbian F, Portaluppi F. (2013b). Administration-time differences in effects of hypertension medications on ambulatory blood pressure regulation. Chronobiol. Int. 30: 280–314.
  • Hermida RC, Ayala DE, Fontao MJ, Mojón A, Fernández JR. (2013c). Ambulatory Blood Pressure Monitoring: Importance of Sampling Rate and Duration—48 versus 24 hours—on the Accurate Assessment of Cardiovascular Risk. Chronobiol. Int. 30: 55–67.
  • Hermida RC, Ayala DE, Mojón A, Fernández JR. (2013d). Blunted sleep-time relative blood pressure decline increases cardiovascular risk independent of blood pressure level—the “normotensive non-dipper” paradox. Chronobiol Int. 30: 87–98.
  • Hermida RC, Ayala DE, Mojón A, Fernández JR. (2013e). Cardiovascular risk of essential hypertension: influence of class, number, and treatment-time regimen of hypertension medications. Chronobiol. Int. 30: 315–327.
  • Hermida RC, Ayala DE, Mojón A, Fernández JR. (2013f). Role of time-of-day of hypertension treatment on the J-shaped relationship between blood pressure and cardiovascular risk. Chronobiol. Int. 30: 328–339.
  • Hermida RC, Ríos MT, Crespo JJ, Moya A, Domínguez-Sardiña M, Otero A, Sánchez JJ, Mojón A, Fernández JR, Ayala DE, on behalf on the Hygia Project Investigators. (2013g). Treatment-time regimen of hypertension medications significantly affects ambulatory blood pressure and clinical characteristics of patients with resistant hypertension. Chronobiol. Int. 30: 192–206.
  • Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, Murata M, Kuroda T, Schwartz JE, Shimada K. (2003). Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 107:1401–1406.
  • Kikuya M, Ohkubo T, Asayama K, Metoki H, Obara T, Saito S, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. (2005). Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality. The Ohasama Study. Hypertension 45:240–245.
  • Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, for the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). (2009). A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150:604–612.
  • Liu M, Takahashi H, Morita Y. (2003). Non-dipping is a potent predictor of cardiovascular mortality and is associated with autonomic dysfunction in haemodialysis patients. Nephrol. Dial. Transplant. 18:563–569.
  • Madhavan S, Ooi WL, Cohen H, Alderman MH. (1994). Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 23:395–401.
  • Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker HAJ, Zanchetti A. (2007). 2007 guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25:1105–1187.
  • Manfredini R, Portaluppi F, Grandi E, Fersini C, Gallerani M. (1996). Out-of-hospital sudden death referring to an emergency department. J. Clin. Epidemiol. 49:865–868.
  • Manfredini R, Boari B, Bressan S, Gallerani M, Salmi R, Portaluppi F, Mehta RH. (2004). Influence of circadian rhythm on mortality after myocardial infarction: data from a prospective cohort of emergency calls. Am. J. Emerg. Med. 22:555–559.
  • Minutolo R, Agarwal R, Borrelli S, Chiodini P, Bellizzi V, Nappi F, Cianciaruso B, Zamboni P, Conte G, Gabbai FB, De Nicola L. (2011). Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease. Arch. Intern. Med. 171:1090–1098.
  • Mojón A, Ayala DE, Piñeiro L, Otero A, Crespo JJ, Moyá A, Bóveda J, Pérez de Lis J, Fernández JR, Hermida RC, on behalf of the Hygia Project Investigators. (2013). Comparison of ambulatory blood pressure parameters of hypertensive patients with and without chronic kidney disease. Chronobiol. Int. 30: 145–158.
  • Moyá A, Crespo JJ, Ayala DE, Ríos MT, Pousa L, Callejas PA, Salgado JL, Mojón A, Fernández JR, Hermida RC, on behalf on the Hygia Project Investigators. (2013). Effects of time-of-day of hypertension treatment on ambulatory blood pressure and clinical characteristics of patients with type 2 diabetes. Chronobiol. Int. 30: 116–131.
  • Nakano S, Fukuda M, Hotta F, Ito T, Ishii T, Kitazawa M, Nishizawa M, Kigoshi T, Uchida K. (1998). Reversed circadian blood pressure rhythm is associated with occurrences of both fatal and nonfatal events in NIDDM subjects. Diabetes. 47:1501–1506.
  • National Kidney Foundation. (2002). K/DOQI clinical practice guidelines on chronic kidney disease: evaluation, classification and stratification. Am. J. Kidney Dis. 39(2 Suppl 1):S1–S266.
  • Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, Matsubara M, Hashimoto J, Hoshi H, Araki T, Tsuji I, Satoh H, Hisamichi S, Imai Y. (2002). Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J. Hypertens. 20:2183–2189.
  • Pogue V, Rahman M, Lipkowitz M, Toto R, Miller E, Faulkner M, Rostand S, Hiremath L, Sika M, Kendrick C, Hu B, Greene T, Appel L, Phillips RA, African American Study of Kidney Disease and Hypertension Collaborative Research Group. (2009). Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hypertension 53:20–27.
  • Portaluppi F, Hermida RC. (2007). Circadian rhythms in cardiac arrhythmias and opportunities for their chronotherapy. Adv. Drug Deliv. Rev. 59:940–951.
  • Portaluppi F, Smolensky MH. (2010). Perspectives on the chronotherapy of hypertension based on the results of the MAPEC study. Chronobiol. Int. 27:1652–1667.
  • Portaluppi F, Montanari L, Ferlini M, Gilli P. (1990). Altered circadian rhythms of blood pressure and heart rate in non-hemodialysis chronic renal failure. Chronobiol. Int. 7:321–327.
  • Portaluppi F, Trasforini G, Margutti A, Vergnani L, Ambrosio MR, Rossi R, Bagni B, Pansini R, degli Uberti EC. (1992). Circadian rhythm of calcitonin gene-related peptide in uncomplicated essential hypertension. J. Hypertens. 10:1227–1234.
  • Portaluppi F, Cortelli P, Avoni P, Vergnani L, Maltoni P, Pavani A, Sforza E, degli Uberti EC, Gambetti P, Lugaresi E. (1994). Progressive disruption of the circadian rhythm of melatonin in fatal familial insomnia. J. Clin. Endocrinol. Metab. 78:1075–1078.
  • Portaluppi F, Vergnani L, Manfredini R, Fersini C. (1996). Endocrine mechanisms of blood pressure rhythms. Ann. N. Y. Acad. Sci. 783:113–131.
  • Portaluppi F, Boari B, Manfredini R. (2004). Oxidative stress in essential hypertension. Curr. Pharm. Des. 10:1695–1698.
  • Portaluppi F, Smolensky MH, Touitou Y. (2010). Ethics and methods for biological rhythm research on animals and human beings. Chronobiol. Int. 27:1911–1929.
  • Portaluppi F, Tiseo R, Smolensky MH, Hermida RC, Ayala DE, Fabbian F. (2012). Circadian rhythms and cardiovascular health. Sleep Med. Rev. 16:151–166.
  • Ríos MT, Domínguez-Sardiña M, Ayala DE, Gomara S, Sineiro E, Pousa L, Callejas PA, Fontao MJ, Fernández JR, Hermida RC, on behalf of the Hygia Project Investigators. (2013). Prevalence and clinical characteristics of isolated-office and true resistant hypertension determined by ambulatory blood pressure monitoring. Chronobiol. Int. 30: 207–220.
  • Salles GF, Cardoso CR, Muxfeldt ES. (2008). Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch. Intern. Med. 168:2340–2346.
  • Smolensky MH, Portaluppi F. (1999). Chronopharmacology and chronotherapy of cardiovascular medications: relevance to prevention and treatment of coronary heart disease. Am. Heart J. 137(4 Pt 2):S14–S24.
  • Smolensky MH, Hermida RC, Castriotta RJ, Portaluppi F. (2007). Role of sleep-wake cycle on blood pressure circadian rhythms and hypertension. Sleep Med. 8:668–680.
  • Smolensky MH, Hermida RC, Ayala DE, Tiseo R, Portaluppi F. (2010). Administration-time-dependent effect of blood pressure-lowering medications: basis for the chronotherapy of hypertension. Blood Press. Monit. 15:173–180.
  • Sturrock ND, George E, Pound N, Stevenson J, Peck GM, Sowter H. (2000). Non-dipping circadian blood pressure and renal impairment are associated with increased mortality in diabetes mellitus. Diabet. Med. 17:360–364.
  • Tripepi G, Fagugli RM, Dattolo P, Parlongo G, Mallamaci F, Buoncristiani U, Zoccali C. (2005). Prognostic value of 24-hour ambulatory blood pressure monitoring and of night/day ratio in nondiabetic, cardiovascular events-free hemodialysis patients. Kidney Int. 68:1294–1302.
  • Varani K, Gessi S, Caiazza A, Rastelli G, Portalluppi F, Borea PA. (1999a). Platelet alpha2-adrenoceptor alterations in patients with essential hypertension. Br. J. Clin. Pharmacol. 47:167–172.
  • Varani K, Portaluppi F, Merighi S, Ongini E, Belardinelli L, Borea PA. (1999b). Caffeine alters A2A adenosine receptors and their function in human platelets. Circulation 99:2499–2502.
  • Varani K, Portaluppi F, Gessi S, Merighi S, Ongini E, Belardinelli L, Borea PA. (2000). Dose and time effects of caffeine intake on human platelet adenosine A(2A) receptors: functional and biochemical aspects. Circulation 102:285–289.
  • Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistell M, Guerrieri M, Gatteschi C, Zampi I, Santucci A, Santucci C, Reboldi G. (1994). Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 24:793–801.
  • Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Pede S, Porcellati C. (1998). Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Hypertension 32:983–988.
  • Verdecchia P, Schillaci G, Reboldi G, Franklin SS, Porcellati C. (2001). Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension. Circulation 103:2579–2584.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.